Another Twist in Genentech v. University of California
The University of California's patent infringement lawsuit against Genentech, concerning Genetics' human growth hormone, was recently heard by a federal court jury in California. The jurors hung on the infringement issue, which will be retried in April 2000. At about the same time, the US supreme Court came down with a decision (in the College Savings Bank case) that will probably result in the dismissal of a mirror image action brought by Genentech in an Indiana federal court. The Court in College Savings bank ruled that state entities -- including state universities -- cannot be sued for damages under federal patent laws. Some have suggested that, by insulating state university patents from infringement suits, there may big IP problems ahead for biotechs. Such concerns are overstated, although patent lawyers for such companies will need to be alert to this significant development.
You may also be interested in...
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.